You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1025 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Aug 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Jan 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
Aug 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jun 2022
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Curative
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Intent: Adjuvant, Neoadjuvant, Palliative
Sep 2019
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Dec 2023
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jun 2024

Pages